Injective ETF Gains Nasdaq Listing Approval as INJ Price Eyes Recovery

Injective (INJ) is gaining market attention after Canary Capital’s Staked INJ ETF secured Nasdaq listing approval, marking another milestone in the network’s expansion into traditional financial markets. The development could improve institutional access to INJ through an investment product offering staking exposure. Meanwhile, the INJ price has regained bullish momentum after breaking above $7.30. Crypto analyst Trader Symba sees further upside potential, identifying $7.55 and the $8.00–$8.20 range as important targets. Injective’s institutional adoption has reached another milestone after Canary Capital’s Staked INJ ETF secured Nasdaq listing approval. The development is highlighted by Eagle.inj, which described the approval as recognition of years of development, innovation, and ecosystem expansion. The ETF is designed to provide investors with exposure to INJ while incorporating staking activities.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TronWeekly.